๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2025-10-07

CKM For Safe Use of SGLT2i in Type 1 Diabetes (NCT07211802)

Utilizing Continuous Ketone Monitors to Enable Safe Use of SGLT Inhibitors in Patients With Type 1 Diabetes

๐ŸŸก Not Yet Recruiting Phase3 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: University of California, San Diego

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.

Who can join: Review the eligibility criteria below.

Location: UCSD - Altman Clinical & Translational Research Institute โ€” La Jolla, California

Age range: 18 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • UCSD - Altman Clinical & Translational Research Institute โ€” La Jolla, California

๐Ÿ“ž Contact the Study Coordinator

Phone: (858) 246-2169

Email: t1dresearch@health.ucsd.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—